TY - JOUR
T1 - Modulation of apoptosis by procaspase-2 short isoform
T2 - Selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization
AU - Droin, Nathalie
AU - Rébé, Cedric
AU - Bichat, Florence
AU - Hammann, Arlette
AU - Bertrand, Richard
AU - Solary, Eric
N1 - Funding Information:
The authors thank Dr Nicholson (Merck, Toronto, Canada) for kindly providing us an anti-caspase-3 Ab. This work was supported in part by grants from the Medical Research Council of Canada (MT-15019) to R Bertrand while E Solary's research group is labeled and granted by the Ligue Nationale Contre le Cancer. R Bertrand is a scholar from the Medical Research Council of Canada and the Cancer Research Society Inc (Canada). N Droin received supports from the MinisteÁ re de l'Education Nationale, de l'Enseignement et de la Recherche, the Société FrancË aise d'Hématologie and the French MinisteÁ re des Affaires EtrangeÁ res.
PY - 2001/1/11
Y1 - 2001/1/11
N2 - Procaspase-2 is one of the cysteine aspartate proteases involved in apoptotic cell death. Alternative splicing of CASP-2 messenger RNA generates a long isoform, procaspase-2L, whose overexpression induces cell death and a truncated isoform, procaspase-2S, whose function remains poorly defined. The present study explored the consequences of procaspase-2S overexpression in U937 human leukemic cells exposed to the topoisomerase II inhibitor etoposide as an apoptotic stimulus. Overexpression of procaspase-2S in U937 cells partially prevented nuclear changes associated with etoposide-induced cell death, as determined by Hoechst 33342 staining of nuclear chromatin and electron microscopy studies. Procaspase-2S also prevented the maturation of apoptotic bodies, delayed phosphatidylserine externalization on the plasma membrane and prevented the cleavage and activation of procaspase-2L. These effects were not observed when the cysteine 289 in the consensus QACRG motif was mutated into a serine. Wild-type procaspase-2S overexpression did not influence the cleavage of procaspase-3, procaspase-7 and poly(ADP-ribose)polymerase nor the fragmentation of nuclear DNA into nucleosome-sized fragments. Altogether, these results indicate that the short isoform of procaspase-2 negatively interferes with selective features of apoptosis, an activity that is suppressed by mutation of the cysteine 289.
AB - Procaspase-2 is one of the cysteine aspartate proteases involved in apoptotic cell death. Alternative splicing of CASP-2 messenger RNA generates a long isoform, procaspase-2L, whose overexpression induces cell death and a truncated isoform, procaspase-2S, whose function remains poorly defined. The present study explored the consequences of procaspase-2S overexpression in U937 human leukemic cells exposed to the topoisomerase II inhibitor etoposide as an apoptotic stimulus. Overexpression of procaspase-2S in U937 cells partially prevented nuclear changes associated with etoposide-induced cell death, as determined by Hoechst 33342 staining of nuclear chromatin and electron microscopy studies. Procaspase-2S also prevented the maturation of apoptotic bodies, delayed phosphatidylserine externalization on the plasma membrane and prevented the cleavage and activation of procaspase-2L. These effects were not observed when the cysteine 289 in the consensus QACRG motif was mutated into a serine. Wild-type procaspase-2S overexpression did not influence the cleavage of procaspase-3, procaspase-7 and poly(ADP-ribose)polymerase nor the fragmentation of nuclear DNA into nucleosome-sized fragments. Altogether, these results indicate that the short isoform of procaspase-2 negatively interferes with selective features of apoptosis, an activity that is suppressed by mutation of the cysteine 289.
KW - Apoptosis
KW - Caspase-2 isoforms
KW - Nuclear changes
UR - http://www.scopus.com/inward/record.url?scp=0035843138&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1204066
DO - 10.1038/sj.onc.1204066
M3 - Article
C2 - 11313953
AN - SCOPUS:0035843138
SN - 0950-9232
VL - 20
SP - 260
EP - 269
JO - Oncogene
JF - Oncogene
IS - 2
ER -